Business Wire

ROBOSENSE

2.3.2023 15:06:52 CET | Business Wire | Press release

Share
RoboSense Launches RS-Fusion-P6, Automotive-Grade Solid-State LiDAR Perception Solution for L4 Autonomous Driving

RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, has announced the launch of its first automotive-grade solid-state LiDAR perception solution for L4 autonomous driving, the RS-Fusion-P6 (P6). With advanced software and hardware support from RoboSense, the P6 provides precise and intelligent environmental perception capabilities, enabling autonomous vehicles to navigate through complex driving scenarios with ease, helping to reduce costs and increase efficiency, and promoting the rapid implementation of large-scale autonomous driving commercial operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005545/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

RS-Fusion-P6 (Photo: Business Wire)

As an automotive-grade solid-state LiDAR perception solution, the P6 perfectly integrates hardware based on two-dimensional MEMS scanning technology and software based on artificial intelligence technology, fully demonstrating the leading level of RoboSense's core technologies in the areas of chips, hardware, and software.

RoboSense's RS-Fusion-P6 solution is designed to be flexible and scalable, making it suitable for a wide range of autonomous driving applications. It can be customized to meet the specific needs of different vehicle platforms and applications, providing a high level of performance and accuracy for all types of autonomous driving scenarios.

The P6 offers high-performance perception capabilities for full-scene environments from start to finish, making it ideal for a range of driving scenarios, including city streets, highways, and everything in between. Equipped with the four M-series solid-state LiDARs, the P6 offers dynamic switching and high-resolution long-distance detection capabilities, enabling intelligent perception over a 360-degree horizontal range, and allowing it to detect traffic conditions up to 200 meters away. The P6 can quickly process this data and provide feedback to the autonomous driving control center, allowing the vehicle to react in milliseconds to any changes in the driving environment.

P6 is equipped with RoboSense self-developed real-time point cloud perception software Perception. Under the intelligent processing of perception, P6 will be able to accurately process complex traffic environment information. Even in challenging driving scenarios, such as mixed traffic and inclement weather conditions, the P6 can accurately identify pedestrians, electric vehicles, cars, trucks, and other obstacles while tracking their speed, acceleration, and location. With this precise environmental perception data, autonomous vehicles equipped with the P6 can make accurate judgments and perform corresponding actions in real-time.

The launch of the P6 demonstrates RoboSense's deep understanding of the pain points in the autonomous driving industry. As the automotive industry continues to rapidly evolve, the P6 provides a reliable and high-performance perception solution that can help to accelerate the adoption of autonomous driving technology. With the P6, RoboSense further expands its product portfolio, which includes mechanical and solid-state LiDAR sensors, perception software, and integrated sensing solutions.

With its advanced perception capabilities and robust product portfolio, RoboSense is well-positioned to help accelerate the adoption of autonomous driving technology across a range of industries, including transportation, logistics, and mobility.

Full article of P6 in detail: https://www.robosense.ai/en/news-show-1690

About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005545/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye